Gefapixant

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.

It was approved for medical use in the European Union in September 2023.

Medical uses
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.

Names
It was named in honour of Geoff Burnstock.